Letter: Albumin-Does formulation matter?

Catherine Yu¹, Afia Iqbal¹, Mayur Garg^{1

2}, Siddharth Sood^{1

2}, Diana Lewis¹

Affiliations

¹ Department of Gastroenterology, Northern Health, Melbourne, Victoria, Australia.
² University of Melbourne, Department of Medicine, Parkville, Victoria, Australia.

Comment

Catherine Yu et al. Aliment Pharmacol Ther. 2023 Jun.

. 2023 Jun;57(12):1482-1483.

doi: 10.1111/apt.17531.

Catherine Yu¹, Afia Iqbal¹, Mayur Garg^{1

2}, Siddharth Sood^{1

2}, Diana Lewis¹

¹ Department of Gastroenterology, Northern Health, Melbourne, Victoria, Australia.
² University of Melbourne, Department of Medicine, Parkville, Victoria, Australia.

No abstract available

Comment in

Letter: Albumin-Does formulation matter? Authors' reply.
Leache L, Gutiérrez-Valencia M, Saiz LC, Uriz J, Bolado F, García-Erce JA, Cantarelli L, Erviti J. Leache L, et al. Aliment Pharmacol Ther. 2023 Jun;57(12):1484-1485. doi: 10.1111/apt.17546. Aliment Pharmacol Ther. 2023. PMID: 37243460 No abstract available.

Meta-analysis: Efficacy and safety of albumin in the prevention and treatment of complications in patients with cirrhosis.
Leache L, Gutiérrez-Valencia M, Saiz LC, Uriz J, Bolado F, García-Erce JA, Cantarelli L, Erviti J. Leache L, et al. Aliment Pharmacol Ther. 2023 Mar;57(6):620-634. doi: 10.1111/apt.17344. Epub 2022 Dec 15. Aliment Pharmacol Ther. 2023. PMID: 36524316

1. Leache L, Gutierrez-Valencia M, Carlos Saiz L, Uriz J, Bolado F, Antonio Garcia-Erce J, et al. Meta-anaylsis: efficacy and safety of albumin in the prevention and treatment of complications in patients with cirrhosis. Aliment Pharmacol Ther. 2023;57(6):620-34.
1. Biggins SW, Paulo A, Garcia-Tsao G, Gines P, Ling S, Nadim M, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74(2):1014-48.
1. Angeli P, Bernardi M, Villanueva C, Francoz C, Mookerjee RP, Trebicka J, et al. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406-60.
1. Patwardhan A, Tjandra D, Rutland K, Beattie W, Sood S. Six months of regular albumin infusions in patients with decompensated liver cirrhosis are associated with reduced admission rate in an Australian tertiary center. J Gastroenterol Hepatol. 2020;35(S1):21-30.
1. Hannah N, Tjandra D, Patwardhan A, Rutland K, Sood S. Real-world survival outcomes in patients with decompensated cirrhosis receiving long term human albumin infusions. J Hepatol. 2022;77(S1):S622.